-
SABCS 2024 | Professor Matteo Lambertini: Optimizing Treatment Strategies for BRCA-Mutated Breast Cancer and Highlights of the SABCS Conference
In the field of breast cancer, the treatment of patients with BRCA gene mutations has always been a research hotspot. Recently, at the SABCS conference, Professor Matteo Lambertini from the San Martino Hospital of the University of Genoa, Italy, shared the latest findings on the treatment of BRCA-mutated breast cancer in depth (abstract number: GS1-08).…
-
ASCO GU 2025 | Professor Toni Choueiri on the Future of Casdatifan in Clear Cell Renal Cell Carcinoma
The VHL-HIF pathway is one of the most commonly activated pathways in clear cell renal cell carcinoma (ccRCC). Loss of von Hippel-Lindau (VHL) gene function leads to the stabilization of hypoxia-inducible factors HIF-1α and HIF-2α, driving tumor growth and progression. The development of HIF-2α inhibitors, including belzutifan and casdatifan, has introduced new therapeutic strategies for…
-
Findings on Hepatic-like Erythropoietin and Its Role in Erythrocytosis
A recent study published in Blood (November 2024) has identified Hepatic-like Erythropoietin Polycythemia (HEP) as a novel cause of hereditary and acquired erythrocytosis. Researchers discovered mutations in the EPO gene,…
-
Findings on Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma
A recent study published in Blood (November 2024) presents results from the Phase 3 inMIND trial, evaluating the addition of tafasitamab to lenalidomide and rituximab in patients with relapsed or…
-
SOHO 2024 | Dr. Jorge E. Cortes Interprets the ASC4FIRST Study, Aiding in the Optimization of First-line Treatment Options for Newly Diagnosed CML
The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML), transforming its management into a chronic disease model and bringing patient life expectancy close to that of the general population. However, some patients experience treatment failure due to intolerance or insufficient response to at least two existing therapies, or…
-
SOHO 2024 | Dr. Grzegorz S. Nowakowski Discusses the Latest Advances in First-line Treatment of DLBCL
Diffuse large B-cell lymphoma (DLBCL), as the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and poses challenges in treatment. Patient prognosis is influenced by various factors, and while the standard R-CHOP regimen is widely used, its efficacy is limited for high-risk groups such as patients with double-hit lymphoma (DHL), necessitating more precise treatment…
-
Dr. Lugui Qiu: Progress Flourishes with a Precision-Based Lymphoma Diagnosis and Treatment System
Lymphoma is a common malignant disease of the lymphatic system that poses a significant threat to public health. China faces a rapidly increasing burden of lymphatic tumors. The GBD 2019 study shows that China accounts for 10.8% of the world’s new cases of Hodgkin lymphoma and 9.8% of the deaths, as well as 20.1% of…
-
World Leukemia Day: Building a Health Defense, Lighting the Flame of Life
September 4 marks “World Leukemia Day,” an initiative launched by the Acute Leukemia Advocates Network, CLL Advocates Network, CML Advocates Network, and Leukaemia Care. The day is dedicated to raising global awareness about leukemia, promoting efforts in prevention, diagnosis, treatment, and recovery. Leukemia, often called “blood cancer,” is a complex disease with high treatment costs…
Connecting Medical Expertise through Media